leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies' Dutch subsidiary to take up new home at Europe's most competitive science region

The building's design is the vision of listed biotechs Genmab and Merus

ImmunoPrecise Antibodies Ltd -
ImmunoPrecise is an international therapeutic antibody discovery company

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) said its Dutch subsidiary U-Protein Express BV has taken a long term lease at the new multi-tenant facility at the Utrecht Science Park, which will encourage collaborations in the life sciences space.

The building's design is the vision of listed biotechs Genmab (NASDAQ:GMAB) and Merus NV (NASDAQ:MRUS) and is said to create a unique hub within the 'innovation ecosystem'.

"We are delighted to move our continuously expanding service activities towards the new building alongside important stakeholders such as Genmab and Merus," said Dr Martin Hessing, General Manager of U-Protein Express. 

READ: ImmunoPrecise Antibodies boosts 2Q revenue on the back of higher-value clients and contracts

"This will enable us to keep in pace with our growing contract research business as Accelerator will give us over 3-4 times current capacity."

Dr Jennifer Bath, President and CEO of  Victoria, British Columbia-based ImmunoPrecise Antibodies, said: "The investments we are making in our European operations are a strong reflection of ImunoPrecise's position in the marketplace and positive outlook for the future.

"The Accelerator provides state-of-the-art facilities that enable our talented team to respond to the increasing demand for our services and innovative technologies."

Contact the author at giles@proactiveinvestors.com

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.44 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $195.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

3 weeks, 4 days ago

2 min read